These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32335059)

  • 21. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
    Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
    Ishiyama H; Satoh T; Kitano M; Tabata K; Komori S; Ikeda M; Soda I; Kurosaka S; Sekiguchi A; Kimura M; Kawakami S; Iwamura M; Hayakawa K
    J Radiat Res; 2014 May; 55(3):509-17. PubMed ID: 24222312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
    Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
    JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
    Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
    JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
    Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
    PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
    de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
    Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
    Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
    Heesterman BL; Aben KKH; van den Bergh ACM; van der Voort van Zyp JRN; Bokhorst LP
    Urol Oncol; 2024 Aug; 42(8):245.e9-245.e18. PubMed ID: 38724349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
    Patel SA; Ma TM; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; DeWeese TL; Tilki D; Ciezki JP; Karnes RJ; Nickols NG; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Boutros PC; Romero T; Horwitz EM; Tendulkar RD; Steinberg ML; Spratt DE; Xiang M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):645-653. PubMed ID: 36179990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
    Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.
    Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
    J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
    Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
    Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    Laing R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Chintzoglou S; Khaksar S; Langley SEM
    BJU Int; 2018 Oct; 122(4):610-617. PubMed ID: 29607601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.